LivaNova (LIVN)

Executive Summary

LivaNova is a global medical device company with a dual focus on neuromodulation and cardiopulmonary products. Its lead platform, VNS Therapy, is approved for drug-resistant epilepsy and is under investigation for difficult-to-treat depression in the RECOVER pivotal study. The company also markets the Essenz Perfusion System for cardiac surgery. LivaNova has faced headwinds from COVID-19-related procedure delays and supply chain issues, but has seen recovery in elective surgeries. Financial performance has been mixed, with neuromodulation growth driven by epilepsy and depression trial progress, while cardiopulmonary remains stable. The company's pipeline includes label expansions and next-gen devices. Given the large addressable market in depression and potential FDA approval, LivaNova is positioned for medium-term growth. Risks include regulatory hurdles, competition, and reimbursement changes.

Upcoming Catalysts (preview)

• Q3 2026RECOVER trial results for VNS Therapy in depression75% success
• Q1 2027FDA label expansion for VNS Therapy in difficult-to-treat depression60% success
• Q2 2026Essenz Perfusion System adoption updates and revenue guidance50% success